Biomea Fusion

We're #hiring a new Clinical Biosample Associate / Sr. Associate in Redwood City, California. Apply today or share this post with your network.

Dear Friends, I am truly pleased to announce that we will be presenting new data from our Phase 2 Study in Type 2 Diabetes next month at ATTD in Amsterdam (The Amstel Dam 😊). This data just became available within the last week. We are developing a first-in-class menin inhibitor, icovamenib, which leverages the body’s own mechanism to rebuild the pool of beta cells (which produce insulin) for adults suffering from diabetes. In the study, patients received icovamenib, an oral dose, once daily, for 12 weeks and are then followed until Week 52. The key endpoint of the study is the reduction in HbA1c (a measure of blood glucose) from baseline at Week 26. In December of last year, we showed for the first time (in history!) that short term treatment can lead to long term improvement in glycemic control. We demonstrated that you could come off a treatment for type 2 diabetes, and observe a continuous improvement in HbA1c over time, as much as 100% improvement after 14 weeks of no treatment. We believe that icovamenib improved the body’s ability to create more insulin on its own. Our goal with icovamenib has always been to fundamentally impact the disease, to restore our patient’s ability to produce insulin, with just a short treatment period. In short, we aim to restore our patient’s natural ability to produce insulin again without the need of chronic therapy. We now know that after 12 weeks of icovamenib treatment, the most insulin deficient patients uncontrolled on standard of care demonstrated the greatest reduction in HbA1c. Importantly, these insulin deficient adults with type 2 diabetes represent one of the most significant unmet medical needs of all adults with type 2 diabetes today. More than 100 million adults with type 2 diabetes worldwide fall into this category. At ATTD, we will show how much c-peptide (a measure of insulin) our patients are now producing on their own. Please join us for this presentation on the web or live.

According to UNESCO Institute for Statistics data, less than 30% of the world’s researchers are women. At Biomea, we believe that having women in science is essential for driving innovation, bringing diverse perspectives, and achieving breakthroughs that benefit everyone. We’re proud to support and celebrate the brilliant women pushing science forward. 👩🔬 Meet some of the incredible women in our chemistry lab, working hands-on at the bench to advance our mission: creating therapies that cure patients of their disease. #WomenInScience #InternationalDayOfWomenAndGirlsInScience #WomenInSTEM #BiomeaFusion #TeamFusion #WeAimToCure

We are happy to announce that Biomea Fusion will be attending the 2025 BIO CEO & Investor Conference in New York, February 10-11, 2025. This event is one of the largest investor conferences on biotechnology.   Our team looks forward to sharing insights about our covalent small molecule therapies, engaging in meaningful discussions, and exploring partnership opportunities that can drive innovation in cancer, diabetes and obesity management.   Interested in partnering with Biomea Fusion or learning more about our groundbreaking work in oncology, diabetes, and obesity? Let’s connect! We’d love to meet with you during the conference.   To schedule a meeting with IR contact: IR@biomeafusion.com  or with BD at: BusinessDevelopment@biomeafusion.com

Today, we honor the life and legacy of Dr. Martin Luther King Jr., a visionary leader who dedicated his life to justice, equality, and unity. His dream continues to inspire us to create a world where everyone has the opportunity to thrive. Let’s take this day to reflect on his teachings, promote kindness, and commit ourselves to the work of building a better future together. #MLKDay #MartinLutherKingJr #EqualityForAll #JusticeAndUnity #InspireChange #BiomeaFusion #WeAimToCure

We're #hiring a new Clinical Scientist/Sr. Clinical Scientist - Diabetes in Redwood City, California. Apply today or share this post with your network.

We're #hiring a new Director, Chemical Development & Drug Substance Manufacturing in Redwood City, California. Apply today or share this post with your network.

We would like to announce Biomea Fusion’s strategic pivot to focus on diabetes and obesity medicines, a move inspired by groundbreaking clinical results for our lead candidate, icovamenib, and our oral small molecule GLP-1 candidate, BMF-650. Read full press release here: https://bit.ly/3DTihvH Key Highlights: Icovamenib: A potential first-in-class menin inhibitor, achieving a 1.5% HbA1c reduction in severe insulin-deficient patients, with durable effects sustained 14 weeks off therapy. Strong synergy with GLP-1-based therapies and a favorable safety profile. Late-stage trials planned for insulin-deficient diabetes patients and GLP-1 combination therapy in 2025. To learn more details about this news and Biomea Fusion please attend our conference during the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 please click here: https://bit.ly/3C9xcRE We’re committed to transforming metabolic care and improving lives. #biotech #diabetes #obesity #innovation #biomeafusion

We're #hiring a new SVP, Clinical Operations in Redwood City, California. Apply today or share this post with your network.

Biomea Fusion Announces New Preclinical Data Supporting Potential of Icovamenib-Semaglutide Combination You can read the full press release here: https://bit.ly/4h7O9el We are pleased to share compelling preclinical data demonstrating the potential of icovamenib, in combination with semaglutide, to significantly enhance outcomes in type 2 diabetes management. Key highlights include enhanced body composition and weight management, improved glycemic control and superior HbA1c reduction. These results underscore the potential of icovamenib to enhance the efficacy of GLP-1 therapies, offering improved glycemic control and metabolic outcomes for patients with type 2 diabetes. Further details will be presented at the J.P. Morgan Healthcare Conference (January 13-15, 2025). Learn more about how Biomea Fusion is advancing innovation in diabetes care at www.biomeafusion.com. #BiomeaFusion #DiabetesInnovation #HealthcareLeadership #ClinicalResearch